eligibility_summary
Eligibility: Adults ≥70 with histologically confirmed, treatment‑naive DLBCL (prior steroids alone allowed), classified as unfit or frail by comprehensive geriatric assessment, with adequate organ function and bone marrow reserve, who provide informed consent. Exclusions: Coexisting non-lymphoma malignancy, active HBV infection, or unstable systemic disease (e.g., active infection, severe cardiac, liver, kidney, or metabolic disease requiring therapy).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests Pola-R2 (polatuzumab vedotin + rituximab + lenalidomide) in newly diagnosed, unfit/frail elderly DLBCL. Polatuzumab vedotin is an antibody–drug conjugate (ADC) targeting CD79b on B cells, after internalization it releases MMAE, a microtubule inhibitor, causing cell-cycle arrest and apoptosis. Rituximab is a chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. Lenalidomide is an immunomodulatory drug (IMiD) that binds cereblon (CRL4CRBN), promoting degradation of IKZF1/3, enhancing T/NK-cell activity, and exerting anti-lymphoma effects. Targeted cells/pathways: malignant CD79b+ and CD20+ B cells, B-cell receptor pathway, microtubules, and immune effector pathways (ADCC/CDC) with immunomodulation via cereblon.